$MLYS News

Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026

Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats

Mineralys Therapeutics (MLYS) Shares New Lorundrostat Data, Is The Stock A Bargain?

UBS Initiates Coverage On Mineralys Therapeutics with Neutral Rating, Announces Price Target of $29

HC Wainwright & Co. Reiterates Buy on Mineralys Therapeutics, Maintains $56 Price Target

Mineralys Therapeutics, Inc. (MLYS) Presents at American Heart Association Hypertension Scientific Sessions 2026 - Slideshow

Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026

Mineralys Therapeutics Reports New Data Of Analysis From Its Pivotal Phase 3 Launch-HTN Study

Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026

Mineralys Therapeutics To Present Five Abstracts At American Heart Association Hypertension Scientific Sessions 2026,

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Mineralys Therapeutics (MLYS) Faces A Fresh Valuation Test On New Lorundrostat Data

Mineralys Therapeutics’ Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026

Mineralys Therapeutics To Present New Long-Term Efficacy And Safety Data From Ongoing Transform-HTN Open-Label Extension Trial Of Aldosterone Synthase Inhibitor Lorundrostat At AHA Scientific Sessions 2026

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

Mineralys (MLYS) Q2 2026 Earnings Call Transcript

Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Mineralys Therapeutics Inc (MLYS) (Q2 2026) Earnings Call Highlights: Strong Cash Position and ...